Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice twitter momo going on, people see how big this is going to be and how cheap we are,,,, 5 mil market cap is a joke. We will be 150m
Imagin Medical, Inc. CSE: $IME approved for the first in-human study using the company's i/Blue Imaging System. https://t.co/27Pt3RQdzF pic.twitter.com/zLb2kFjlVN
— Equity Insight (@EquityInsightCA) September 28, 2017
$ime let's say 4 months. They will absolutely get fda approval. Hello 150m market cap 😆 it's so cheap
— Big Bird (@BigBirdofBayst) September 27, 2017
Anyone see the news on $imexf damn I wish I had more...
— Jason Spatafora (@WolfOfWeedST) September 28, 2017
Imagin Medical to resume trading Sept. 28
2017-09-27 17:05 ET - Resume Trading
Imagin Medical Inc. wil resume trading, effective at 5 a.m. PT on Sept. 28, 2017.
Holly SHIT !!!
IMAGIN MEDICAL RECEIVES APPROVAL FOR 1ST IN-HUMAN RESEARCH STUDY
The University of Rochester (UR) Research Study Review Board (RSRB) has approved the first in-human study using Imagin Medical Inc.'s i/Blue imaging system. Recruitment of subjects will begin immediately and continue until the study is completed, which is expected to be a three-month process. More information can be found on the Clinical Trials website.
The pilot study, entitled "Near Infrared Fluorescence Imaging for Bladder Cancer Detection," is sponsored by Dr. Edward Messing, chair of urology at the University of Rochester Medical Center and the study's principal investigator. The primary purpose of the study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumours using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).
The company has expressed confidence that the 10-patient study will validate previous bench-testing results that have shown: (1) physicians will be able to see the cancer in 10 minutes versus the full hour required by today's technology; and (2) the white and fluorescence images will blend into one to put the cancer into context within the bladder.
"We're very excited to receive the approval. It's a major milestone for Imagin and we're eager to see the study begin," said Jim Hutchens, Imagin's president and chief executive officer. "Based on previous testing, we anticipate positive results that will bring us closer to delivering this life-saving technology to the marketplace."
About Imagin Medical Inc.
Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin's initial target market is bladder cancer, a major cancer around the world, the sixth-most prevalent in the United States and the most costly cancer to treat due to a greater-than-50-per-cent recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.
We seek Safe Harbor.
Great article
Banking Is Only The Beginning: 30 Big Industries Blockchain Could Transform
https://www.cbinsights.com/research/industries-disrupted-blockchain/
Sounds like NVTQF has this almost nailed:
Additionally, the company has been reviewing blockchain technologies that would be synergistic to Novateqni's existing business verticals. The markets for blockchain can be anywhere from biometrics based payments and secure money transfer to voter registration, voting and voter verification. It is also potentially useful for pre payments for utilities and services.
CEO here owns 13 million shares, 1/3 of the entire float !!
NovaTeqni Currently Reviewing Adoption of Block Chain Technologies
September 27, 2017 / TheNewswire / Calgary, Alberta – NovaTeqni Corporation (“ NovaTeqni ” or the " Company ") (TSXV:NTQ, OTCQB:NVTQF) is pleased to update shareholders with the activities of the Company over the last few months. The previously announced Mobizent deal is being fulfilled with testing of MobiCONNECT and development of the biometrics enabled mobile MobiCHK II computer is in full progress. Both products are aimed at the law enforcement sector in the United States and elsewhere.
NovaTeqni has also progressed its range of Pre-paid off Grid Solar Power Packs for homes and small businesses. The Nova Solar Power Systems have online data connectivity allowing easy pay-as-you-go top up and telemetry for efficient remote support. This makes the purchase cost much lower for home owners who then pay for electricity as and when it is required on a pay-as-you-go basis. The cost effective system will be especially useful in areas such as Africa where many millions of homes in rural areas and small towns have no grid connected power. It is anticipated that a micro credit facility will allow users to obtain power on credit in certain cases, this is a feature able to be provided via the online connectivity of the system. The small business system is able to provide power to small businesses, schools, clinics, etc. These systems will be able to power a DC operated water filter system as well as a fridge, TV with satellite receiver, lights and small computers. This sector is receiving considerable investment attention. NovaTeqni has to date supplied close to 10,000 of its low power solar power kits to entities including the United Nations (UN).
Additionally, the company has been reviewing blockchain technologies that would be synergistic to Novateqni's existing business verticals. The markets for blockchain can be anywhere from biometrics based payments and secure money transfer to voter registration, voting and voter verification. It is also potentially useful for pre payments for utilities and services.
Gerhard Mynhardt, CEO of Novateqni stated , “We are very pleased to be completing the work for Mobizent and the team is working hard on growing our presence in our areas of expertise.”
http://www.prnewswire.com/news-releases/biometrics-infusion-into-blockchain-technology-is-pushing-mobile-payments-and-bitcoin-industries-to-new-levels-648204543.html
Biometrics Infusion into Blockchain Technology is Pushing Mobile Payments and Bitcoin Industries to New Levels
PALM BEACH, Florida, September 27, 2017 /PRNewswire/ --
The blockchain has proven to be an ingenious invention. The innovation of permitting digital information to be distributed but not copied, blockchain technology is an incorruptible digital ledger of economic transactions that can be programmed to record not just financial transactions but virtually everything of value. Active companies in the markets today include: NovaTeqni Corporation (OTC: NVTQF) (TSX-V: NTQ), HIVE Blockchain Technologies LT (TSX-V: HIVE), BTL Group Ltd (TSX-V: BTL) (OTC: BTLLF), Bitcoin Services, Inc. (OTC: BTSC), MGT Capital Investments, Inc. (OTC: MGTI)
NovaTeqni Corporation (OTCQB: NVTQF) (TSX-V: NTQ.V) is pleased to update shareholders with the activities of the Company over the last few months. The previously announced Mobizent deal is being fulfilled with testing of MobiCONNECT and development of the biometrics enabled mobile MobiCHK II computer is in full progress. Both products are aimed at the law enforcement sector in the United States and elsewhere.
NovaTeqni has also progressed its range of Pre-paid off Grid Solar Power Packs for homes and small businesses. The Nova Solar Power Systems have online data connectivity allowing easy pay-as-you-go top up and telemetry for efficient remote support. This makes the purchase cost much lower for home owners who then pay for electricity as and when it is required on a pay-as-you-go basis. The cost effective system will be especially useful in areas such as Africa where many millions of homes in rural areas and small towns have no grid connected power. It is anticipated that a micro credit facility will allow users to obtain power on credit in certain cases, this is a feature able to be provided via the online connectivity of the system. The small business system is able to provide power to small businesses, schools, clinics, etc. These systems will be able to power a DC operated water filter system as well as a fridge, TV with satellite receiver, lights and small computers. This sector is receiving considerable investment attention. NovaTeqni has to date supplied close to 10,000 of its low power solar power kits to entities including the United Nations (UN).
Additionally, the company has been reviewing blockchain technologies that would be synergistic to Novateqni's existing business verticals. The markets for blockchain can be anywhere from biometrics based payments and secure money transfer to voter registration, voting and voter verification. It is also potentially useful for pre payments for utilities and services.
Gerhard Mynhardt, CEO of Novateqni stated, "We are very pleased to be completing the work for Mobizent and the team is working hard on growing our presence in our areas of expertise."
PreveCeutical Medical (PREV : PRVCF) hails deal with cannabis producer, which will boost its Sol-Gel program
Preveceutical Medical Inc. has entered into a strategic research and development supply agreement dated effective Sept. 18, 2017, with a licensed producer of medical cannabis under Health Canada's Access to Cannabis for Medical Purposes Regulations, whereby the LP will supply samples of cannabis-derived products and ingredient information for use by Preveceutical in its research and development program for the commercialization of sol-gels for the nasal delivery of medical compounds, including cannabinoids.
PreveCeutical's Chairman and CEO, Mr. Stephen Van Deventer commented, "We are extremely pleased with the agreement between PreveCeutical and the LP. The LP is an acknowledged industry leader in Canada in terms of its high-quality, high-margin derivative products that are manufactured under rigorous standards regarding processes, testing and transparency. We believe that having access to high quality cannabis oil and dried cannabis plant extracts from the LP will greatly assist PreveCeutical with the continued development of the Sol-Gel Program."
Commercial Terms of Supply Agreement
Under the terms of the Supply Agreement, the LP will provide the Company with prescribed strains of cannabis oil and dried cannabis plant extract along with certain ingredient and excipient specifications (the "Deliverables"). As consideration for the Deliverables and subject to acceptance by the Canadian Securities Exchange, the Company will grant to the LP:
non-transferable options (the "Options") to acquire that number of common shares in the capital of the Company (being 2,565,000 common shares) having an aggregate value of CAD 2 million at an exercise price equal to the closing price of PreveCeutical's common shares on the Canadian Securities Exchange on the date of execution of the Supply Agreement, which Options will be exercisable for a period of 24 months from the effective date of the Supply Agreement;
a right of first refusal (the "Financing ROFR") to subscribe for the whole or a portion of any equity financing conducted by the Company for a period of 24 months from the effective date of the Supply Agreement; provided that if the LP exercises the Financing ROFR, then any Options that have not yet been exercised by the LP will expire within 15 days of the date of such exercise; and
a right of first refusal (the "Licensing ROFR) to negotiate a non-transferable license for the non-exclusive use by the LP of the sol-gel technology developed by the Company; provided that in the event that the LP declines to exercise the Licensing ROFR, it will have the non-assignable right to receive a royalty on the gross revenues of the Company from the sale of the Company's sol-gel technology in Australia and/or Canada to a maximum of CAD 2 million as follows:
Aggregate Gross Revenues (CAD)Royalty Payable (%)
0 to 500,000 8%
500,001 to 1,000,000 6%
1,000,001 to 5,000,000 5%
5,000,001 to 10,000,000 3%
Over 10,000,000 2%
The provision of the Deliverables by the LP to the Company is conditional on the LP obtaining an export licence and complying with any other applicable regulatory requirements for the delivery of the Deliverables to Australia, as well as on the Company obtaining an import license and complying with any other regulatory requirements for the same. The Supply Agreement does not grant or transfer to the Company any intellectual property rights in the Deliverables, and vice versa does not transfer to the LP any intellectual property rights in the sol-gel technology.
Sol-Gel Nasal Delivery System
The Sol-Gel Program is focused on developing what the Company believes will be the first FDA approved, nose-to-brain delivery system of cannabinoids intended to provide relief for a range of ailments, such as pain, inflammation, seizures, and neurological disorders. The Company is seeking to design universally-patient friendly proprietary nasal formulations that can be used in children and adults alike.
PreveCeutical's Sol-Gel Program is being conducted by the Company through UniQuest Pty Limited ("UniQuest") pursuant to a research and development agreement dated April 22, 2017. For further information regarding the Company's research and development agreement with UniQuest, please refer to the Company's news release dated April 24, 2017. Any common shares of PreveCeutical issued upon the exercise of the Options will be subject to a hold period in Canada of four months and one day from the date of issuance.
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
We seek Safe Harbor.
PreveCeutical Begins Trading on the OTCQB
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2017) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that the Company's application to have its common shares listed on the OTCQB Venture Marketplace ("OTCQB") in the United States has been approved and that the Company's common share began trading on September 15, 2017, under the symbol "PRVCF".
The OTCQB is for early-stage and developing United States and international companies. To be eligible for trading, companies must be current in their financial reporting, pass a minimum bid price test and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.
PreveCeutical's Chairman and CEO, Mr. Stephen Van Deventer commented, "We are extremely pleased to be able to upgrade to quote on the OTCQB. This listing will enable us to expand our U.S. shareholder base as well as offer the Company's existing U.S. shareholders a more transparent and efficient platform to obtain quotes and trade PreveCeutical securities."
Top 4 Companies Reinventing Cannabinoid Delivery
Sol-Gel Nasal Delivery
Soft gels have become a popular delivery mechanism since they are easy to administer, familiar to patients, and may contain a variety of different chemicals designed for slow-release and other features that improve the safety and efficacy profile of the active ingredients.
PreveCeutical Medical Inc.’s (CNSX: PREV) Sol-Gel technology encapsulates cannabinoids in a soluble form, while nanomicelles provide tissue permeation enhancing properties. Local tissue irritation is avoided as cannabinoids are in-solution and can be presented at lower doses. At the same time, Sol-Gels can remain in place for extended periods of time, which can reduce the administration times to once or twice weekly rather than daily.
The company has pioneered a novel process for preparing insoluble drug-containing nanomicelles and incorporating them into Sol-Gels in conjunction with the Parekh group at PACE-UQ. The team plans to file a provisional patent application around the single phase Sol-Gels for nasal delivery, which could vastly improve bioavailability relative to other therapeutics that are already on the market.
Preveceutical Medical Inc. has engaged the Susan Blond Group Inc. to provide publicity services and has appointed Susan Blond as the company's director of publicity.
Ms. Blond, principal of the Susan Blond Group, will assist PreveCeutical in initiating, implementing and executing the Company's publicity plan.
A $12 Billion Takeover Says That Gene Therapy Cancer Cures Are Big Business
https://www.technologyreview.com/the-download/608753/a-12-billion-takeover-says-that-gene-therapy-cancer-cures-are-big-business/
$PRVCF PreveCeutical signs Research and Option Agreement with UniQuest Pty Limited for Developing Dual-Gene Therapy Treatment for Diabetes and Obesity
https://globenewswire.com/news-release/2017/07/17/1047374/0/en/PreveCeutical-signs-Research-and-Option-Agreement-with-UniQuest-Pty-Limited-for-Developing-Dual-Gene-Therapy-Treatment-for-Diabetes-and-Obesity.html
A Less Controversial Application For Gene Editing: Obesity And Diabetes
http://www.huffingtonpost.ca/jason-tetro/a-less-controversial-application-for-gene-editing-obesity-and-d_a_23074666/
Gilead just handed a revolutionary kind of cancer treatment a $12 billion endorsement
http://www.businessinsider.com/why-gilead-bought-kite-pharma-for-12-billion-2017-8
"We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer," the FDA commissioner, Scott Gottlieb, said in a statement. "New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.
http://www.businessinsider.com/fda-approves-novartis-car-t-cancer-treatment-2017-8
$PRVCF going for the DTC...going to get interesting really soon !!!
2017-08-16 06:18 ET - News Release
PREVECEUTICAL MEDICAL BEGINS TRADING ON THE OTC MARKET
Preveceutical Medical Inc. is quoting its common shares for trading on the OTC Pink market, under the symbol PRVCF.
In connection with the quotation of its shares on the OTC, the company is completing its filings for the quotation of its shares on the OTCQB market. The company has also made an application for its common shares to be DTC eligible and expects to receive this designation within the next 30 days.
Preveceutical's chairman and chief executive officer, Stephen Van Deventer, commented, "An OTC quotation will provide further liquidity for both existing and new shareholders and increase Preveceutical's presence in the United States."
Isodiol International Inc. Announces Distribution Agreement for South America
https://www.centralcharts.com/en/news/930907-isodiol-international-inc-announces-distribution-agreement-for-south-america
VANCOUVER, British Columbia, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:LAGBF) (FSE:LB6A.F) (the “Company” or “Isodiol”) a global cannabinoid innovator specializing in the development of pharmaceutical and consumer products announces it has signed a distribution partnership with FarmaUSA™, a leading global wholesale distributor of imported pharmaceutical products in South America. This is the latest action taken by the Company to further secure its position in the Brazilian market and provide for an additional expansion into greater South America.
This deal will expand Isodiol's product Isoderm™ in Brazil and across South America by utilizing FarmaUSA's existing distribution and doctor network to increase the presence of Isoderm™ Direct Effect Technologies™. FarmaUSA will facilitate physician conferences across the country to further educate healthcare professionals on the benefits of Isoderm™ while continuing to work with regulatory officials at Agência Nacional de Vigilância Sanitária (ANVISA) for commencing a clinical trial.
Marcos Agramont, CEO of Isodiol International Inc. stated, “This is a major milestone in the development of our international expansion strategy. FarmaUSA is very well respected among healthcare professionals in South America to help facilitate this process for the Company. I anticipate a dramatic increase in the amount of prescriptions being written by physicians in these markets as we move forward and head towards a clinical trial in the coming months.”
Djalma Nogueria, CEO of FarmaUSA stated, “We are very excited to work with Isodiol in bringing Isoderm™ to the South American market. We have seen a tremendous initial response from the health professionals who have commenced prescribing the product and we anticipate this to continue. With our Isodiol partnership now established, we are well positioned to enter additional markets in South America and become the leader in the space.”
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of a 99%+ pure pharmaceutical grade cannabinoid crystalline isolate derived from exempt parts of the hemp plant, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue International expansion into Latin America, Asia and Europe.
$PRVCF HUGE NEWS !!
PREVECEUTICAL MEDICAL AND SPORTS 1 MARKETING ANNOUNCE JOINT VENTURE TO DEVELOP A THERAPY FOR CONCUSSIONS
https://sports1marketing.com/
Preveceutical, Sports 1 to develop concussion therapy
2017-08-30 06:34 ET - News Release
Mr. Stephen Van Deventer reports
PREVECEUTICAL MEDICAL AND SPORTS 1 MARKETING ANNOUNCE JOINT VENTURE TO DEVELOP A THERAPY FOR CONCUSSIONS
Preveceutical Medical Inc. and Sports 1 Marketing (S1M) have entered a joint venture to develop a therapy geared toward athletes who suffer from concussions (mild traumatic brain injury) (TBI).
Through PreveCeutical's current Research and Development program connected to the Caribbean Blue Scorpion venom, PreveCeutical and S1M believe that there is therapeutic potential in the peptides and proteins to potentially treat TBI.
According to the Centers for Disease Control and Prevention website, a severe TBI not only impacts the life of an individual and their family, but it also has a large societal and economic toll. The estimated economic cost of TBI in 2010, including direct and indirect medical costs, is estimated to be approximately $76.5 billion. Additionally, the cost of fatal TBIs and TBIs requiring hospitalization, many of which are severe, account for approximately 90% of the total TBI medical costs.
PreveCeutical's Chairman and CEO, Mr. Stephen Van Deventer commented, "We are encouraged from the fact that the Caribbean Blue Scorpion venom peptides bypasses the blood brain barrier and attaches to the abnormal cells, this is an indicator that we are going in the right direction. We are delighted to have this opportunity of working with S1M on this exciting program where we hope to be able to help millions of people. David Meltzer and Warren Moon are icons in the professional sports industry. Their vision to help a lot of people are identical to ours."
S1M's Co-Founder and CEO, David Meltzer commented, "With PreveCeutical's outstanding research and leadership team, we are excited to be partnered up with such an innovative and industry leading group of people."
Completion of the joint venture will be subject to a number of conditions including the approval of the Canadian Securities Exchange.
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive therapies utilizing organic and nature identical products.
The Company currently has one product available for sale, the CELLB9trademark Immune System Booster. CELLB9trademark is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. The active potentiated ingredients in the Blue Scorpion venom appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colourless and odourless and can be administered orally.
$PRVCF I'm expecting BIG things here !!!
https://preveceutical.com/
PRVCF$ looking great today !!!
Expect BIG things !!!
https://preveceutical.com/
ISOLF ''We continue to develop our infrastructure in Latin America and will begin the due diligence process of expanding into the European and Asian markets in the near future."
China Has Quietly Become A Cannabis Superpower
Many things are going behind curtains...
1) Bigger Sales coming
Q1 revenues of $4,919,693.
2) More Profit coming
Q1 profits of $897,596
3) New countries coming
We continue to develop our infrastructure in Latin America and will begin the due diligence process of expanding into the European and Asian markets in the near future."
4) Deals with LP's more coming....
Isodiol International Inc. signs definitive licensing agreement with Canopy Growth Corporation for Canadian and international distribution
5) Acquisitions coming
''This funding support allows us to further enhance our global expansion and move forward on strategic acquisitions.''
Big acquisition in the works imo....
Isodiol arranges $25-million debenture financing
2017-08-21 18:52 ET - News Release
Mr. Marcos Agramont reports
ISODIOL INTERNATIONAL INC. ANNOUNCES $25,000,000 CONVERTIBLE DEBENTURE FINANCING
Isodiol International Inc. has signed a convertible debenture financing for $25-million with Alumnia Partners.
Marcos Agramont, chief executive officer of Isodiol, stated: "Our focus remains to grow revenues by developing the Isodiol brand domestically and in international markets. This funding support allows us to further enhance our global expansion and move forward on strategic acquisitions. Innovation and development of IP is what separates us from our competitors, and we will continue to make this a priority."
"We're pleased to help support Isodiol's plans to realize one of the industry's long-standing aspirations of truly normalizing and bringing regulated cannabis into the mainstream," added Adi Nahmani, managing member of Alumina Partners. "As demonstrated by their growth, Isodiol's talented team is working diligently on many fronts to make tomorrow's idealistic dream a commercial reality today."
Pursuant to the terms of the offering, the debenture has no minimum drawdown requirement and has a 24-month term at an annual interest rate of 8 per cent with no upfront fees or associated costs. Alumina Partners will commit up to $25-million with conversion terms consisting of one common share and one-half of one common share purchase warrant, at discounts ranging from 15 per cent to 25 per cent of the market price of the shares. The exercise price of the warrants will be at a 50-per-cent premium over the market price of the shares.
About Isodiol International Inc.
Some German exposure just released, these things tend to come out before a big push or news.
Urgent: Strong numbers and giant leaps ahead
New 1,000% cannabis hot stock after 10.866% with Aurora cannabis
Our Cannabis Hot Stock Isodiol International Inc. (ISIN CA46500L1013 / WKN A2DTBH, ticker: 7C5, CSE: ISOL) is about to be launched in the second quarter of 2017. In the first quarter of 2017, $ 4.92 million and a profit of $ 897,000. The very likely quarterly figures for Q2 2017 will be reported in a few days. According to corporate investors, institutional investors are also prepared to put an eight-digit dollar amount into the acceleration of the already rapid growth of our cannabis hot stock. After gaining up to 1,475% of GW Pharmaceuticals cannabis shares, 10,866% of Aurora Cannabis and 53,700% of cannabis stocks from Canopy Growth, you can be right from the start when our new Cannabis Hot Stock Isodiol International (ISIN CA46500L1013 / WKN A2DTBH, ticker: 7C5, CSE: ISOL) to the stock market. From 10,000 EUR were up to 5.380.000 EUR. Do not miss this stock chance. Our new cannabis share recommendation Isodiol International Inc. is currently one of the fastest growing cannabis companies and has recently reported the breakeven. We expect breakthrough news and a course rally for our new Cannabis Hot Stock in the coming week.
From EUR 10,000 up to EUR 5.380.000 - Do not miss this stock chance
Up to 53,700% profit could be attributed to early investors with the cannabis shares of Canopy Growth Corp. do. The shares of the current number one of the cannabis industry exploded from a maximum of 53.700% from 0.025 CAD at the end of 2013 in only three years in the top at 13.45 CAD. From a stock purchase of 10,000 EUR a stately property of 5.380.000 EUR. Do not miss this unique stock chance. Currently, Canopy Growth is valued at EUR 1 billion - more than 93 times the current market value of our new cannabis Hot Stock Isodiol International Inc ..
Natural cannabis develops into the general purpose weapon of modern medicine
Unique and highly profitable business model
Our new Cannabis Hot Stock Isodiol International Inc. has developed a unique and highly profitable business model. The Cannabis Aktientip does not dispense with capital-intensive cannabis production. Instead, exclusive purchase contracts with cannabis producers are closed. Our Cannabis Hot Stock enhances the raw material of cannabis in the form of medical cannabis products and branded cannabis products for recreational use. In branded products the big profit is. Not the sugar-producing farmers, but the producers of sugary beverages, e.g. Coca Cola achieve the highest profit margins. In contrast to many other highly acclaimed cannabis companies, our Cannabis Hotstock Isodiol International Inc. already generates rapidly increasing sales and even profits.
The natural cannabinoid extract ISODIAL has already passed the clinical test phases successfully and is in marketing to pharmaceutical companies, chemical distributors, cosmetics manufacturers and the retail trade.
The medical cannabis product ISO Medical has also successfully passed the clinical tests and sales have already started. The target customers are pharmacies and health care providers.
5.9 million CAD sales and 850,000 CAD annual surplus
3.191% Sales growth - break even in the first financial year
Our Cannabis Aktientip of the Break Even already succeeded in the first operating year. Our Cannabis Hot Stock achieved a yearly profit of 850,478 CAD in the last year. Sales revenues exploded by 3.191% from $ 33,735 in May 2016 to $ 1,109 million in December 2016. In the first quarter of 2017, our new Cannabis Hot Stock generated revenues of $ 4.92 million and a profit of $ 897,000.
For the full year 2017, the top management already expects sales of CAD 23 million and an annual surplus of C $ 3.75 million.
The figures for the second quarter of 2017, which are expected in a few days, are expected to exceed the high expectations in business circles. A course rally for our Cannabis Hot Stock should be the logical result.
Rapid growth in sales from 5.9 million CAD in 2016 to 77 million CAD in 2020. Profit explosion from $ 0.85 million in 2016 to $ 20.95 million in 2020
The Proof of Concept has already succeeded in our Cannabis share recommendation Isodiol International Inc. However, the rapid growth has just begun. So be there when the next success train on the stock market. The management has already proved that it has developed a unique and highly profitable business model. The company expects a rapid growth in sales and earnings in the coming years. Revenue is expected to increase from $ 5.9 million in the past year 2016 to $ 77.4 million in 2020. The profit is expected to explode in the same period from $ 0.85 million to $ 20.95 million.
Completely underestimated in industry comparison - competitors rated up to 160 times higher
Our Cannabis Actientip Isodiol International Inc. is currently underestimated in the industry comparison. Thanks to its unique business model, our Cannabis Hot Stock is highly profitable, in contrast to many higher rated competitors. The Cannabis shares of GW Pharmaceuticals have risen by 1.475% from USD 8.51 to USD 134.02 within a few years. From a stock investment of 10,000 EUR was a small property of 157,485 EUR. GW Pharmaceuticals is currently valued at 1.72 billion euros on the stock exchange - more than 160 times as much as our new Cannabis Hot Stock Isodiol International Inc .. of only EUR 10.67 million.
Breaking news ahead - Strong quarterly figures and giant leaps ahead
We expect the groundbreaking news for our Cannabis Hot Stock Isodiol International Inc. in the coming weeks. The results for the second quarter of 2017, which are expected in a few days, are expected to significantly exceed the high expectations. In addition, our Cannabis Aktientip Unternehmenskreise is directly before the conclusion of further Riesendeals. We therefore expect a course rally for our Cannabis Hot Stock Isodiol International Inc.
Strong Outperformer - Price target 24M 1,50 EUR - 711% Kurschance
We therefore reaffirm our assessment of "Strong Outperformer" for our Cannabis Hot Stock Isodiol International Inc. The target price for 12 months is estimated at EUR 1.00 for our Cannabis stock recommendation. This corresponds to a stock chance of 441% for brave and risky investors with our Cannabis Aktientip. In the case of 24 months we consider a target price of 1.50 EUR for our Cannabis Hot Stock as realistic. This corresponds to a stock performance of 711% with our Cannabis share recommendation.
Top Cannabis Infused Drinks
$ISOLF Pot O Coffee
#Breaking: FDA Declares CBD Beneficial
Yesterday, the FDA called for comments to help the United Nation’s World Health Organization (WHO) decide whether 17 controversial drugs should face international restrictions under the 1971 Convention on Psychotropic Substances.
Out of the listed substances, cannabidiol (CBD) was the only one that the FDA called beneficial. The agency issued the following statement:
https://technical420.com/cannabis-article/breaking-fda-declares-cbd-beneficial
Love it !
The company continues to develop and gain penetration with its pharmaceutical-grade products in Latin America and remains committed to increasing its top-line revenues and ultimately increasing its profitability.
We continue to develop our infrastructure in Latin America and will begin the due diligence process of expanding into the European and Asian markets in the near future."
Isodiol to change OTC symbol to ISOLF Aug. 3
ISODIOL INTERNATIONAL INC. ANNOUNCES OTC SYMBOL CHANGE
The Financial Industry Regulatory Authority Inc. has approved Isodiol International Inc.'s OTC voluntary symbol change from LAGBF to ISOLF to better reflect the company's current name.
The changes will be reflected at the opening of the market on Aug. 3, 2017.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade cannabis compounds and the industry leader in the manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for hemp-derived cannabinoids, microencapsulation and nanotechnology for the highest-quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries, and will aggressively continue international expansion into Latin America, Asia and Europe.
Comparables !! Enough said !!
View comparable chart
Most Undervalued
MOST UNDERVALUED WEED STOCK IN THE OTC
Guys It's going to $1 short term...watch.
PP is closed now. That's went they tend to let her rip.
LIBERTY ONE LITHIUM ANNOUNCES CLOSING OF PRIVATE PLACEMENT
On canadian side 344k bid at 67 !!! Someone wants in big time $LBY
The CAD symbol (LBY) needs to catch up, 67 should be 74.
Guys the run hasn't started yet. This is load up time before the big push.
Not much time left.
http://www.firmenpresse.de/pressrelease546227/aurora-and-radient-technologies-announce-positive-results-from-research-joint-venture.html
Aurora and Radient Technologies Announce Positive Results from Research Joint Venture
Collaboration Validates that Radient's Proprietary Extraction Technology Offers Superior Cannabinoid Extraction Efficiency and Significantly Higher Throughput than Conventional Processes
/EINPresswire.com/ -- VANCOUVER, BRITISH COLUMBIA and EDMONTON, ALBERTA--(Marketwired - Jun 5, 2017) - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX VENTURE:ACB)(OTCQX:ACBFF)(FRANKFURT:21P)(WKN:A1C4WM) and Radient Technologies ("Radient") (TSX VENTURE:RTI) are pleased to announce the successful completion of their Joint Venture Research Activity ("JV"), confirming the effectiveness of Radient's proprietary MAP™ Technology and associated continuous flow design for extracting cannabinoids from dried cannabis.
On December 14, 2016, Radient and Aurora executed a Memorandum of Understanding ("MOU") to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized cannabinoid extracts. The first element of the collaboration was the execution of a joint research project to assess the feasibility of applying Radient's proprietary technology for the extraction of cannabinoids from cannabis, including the establishment of parameters of extraction yields, recovery rates of available cannabinoids, purity of the extracts obtained, and the determination of cannabinoids and terpene profiles. The feasibility study also included an assessment of the potential processing throughput achievable using Radient's large-scale continuous-flow MAP™ extractor, based upon established extraction conditions.
Radient's MAP™ technology enables precise control of temperature and extraction time of continuously flowing material, both of which affect purity and extract profile. This careful control of extraction parameters and product quality is something that is impossible to achieve at large scale using conventional methods. Extremely high (quantitative) recovery of available cannabinoids is possible in extraction times that are shaved from hours to minutes.
The study was conducted in two phases: bench-scale screening experiments of MAP™ extraction conditions; and scaled-up experiments under preferred extraction conditions. The analytical data from the research project were verified and confirmed by Anandia Labs Inc., a leading Canadian independent cannabis testing laboratory.
Key findings:
Consistently high extraction efficiencies of up to 98% (quantitative recovery) were observed compared to 80 - 85% typical for conventional technologies;
Exceptionally short processing times of as little as five minutes were achieved, as compared to approximately 6 hours for currently used commercial technologies;
Consistently high purity levels were observed for the extracts produced, at least on par with those achieved using conventional methods;
The research data indicate that throughputs in excess of 1,500 kg per day can potentially be achieved using Radient's proprietary large-scale continuous-flow MAP™ extractor, many times higher than what can be achieved using conventional methods;
Replication of this technology in other jurisdictions on a larger or smaller scale is feasible;
Extract profiles obtained during the project show near full preservation of cannabinoid and terpene profiles in the extracts.
Based on the positive results of the study Radient and Aurora have agreed to negotiate an exclusive development and commercialization agreement for the use of Radient's technology, and to continue their exclusive Joint Venture for additional scientific Research and Development of cannabis and hemp products.
"These results clearly validate the game changing nature of Radient's technology for the cannabis sector," said Terry Booth, CEO of Aurora. "The ability to produce high-purity concentrates at very high throughputs, while preserving terpene profiles, will provide a substantial competitive advantage for us in addressing the high- growth concentrates market. We see a number of factors that will require a significant expansion of production capacity for extracts, including our own expanding national and international footprint, the continued strong growth of the medical market in Canada, Germany and Australia, and the commencement of Canadian adult usage sales anticipated for July of 2018. The exclusive use of Radient's technology positions us as the clear leader in this field, which we believe will enable Aurora to capture a significant share of this high-margin market."
Booth concluded, "Aurora is very pleased to be a significant shareholder of Radient, and as part of our partnership with them, plan on continuing to hold a significant position in Radient."
Radient's CEO, Denis Taschuk, stated, "The positive outcome of the joint research project is a key milestone in the commercial development of Radient. With these results in our pocket, we are now able to commercialize our technology in what has become the fastest growing sector of the North American economy. We are very pleased to embark on this journey with Aurora, who have proven to embrace innovation and who have developed one of the strongest brands within the cannabis industry, both in Canada and internationally."
Radient also announces that, pursuant the terms of the convertible debenture issued to Aurora on February 13, 2017, Radient will make the first quarterly interest payment of $50,000 to Aurora through the issuance of additional units to Aurora ("Units"). Each Unit consisting of one common share and one common share purchase warrant.
The interest payment was payable to Aurora on May 13, 2017 and the conversion price for the issuance of the Units is $0.48 being Radient's closing trading price on Friday May 12, 2017. Based on this conversion price, Radient will issue 104,167 common shares and 104,167 common share purchase warrants to Aurora in satisfaction of the interest payment. Each common share purchase warrant will entitle Aurora to acquire one additional common share of Radient at an exercise price of $0.48 per share. The issuance of the Units to Aurora is subject to final approval of the TSX Venture Exchange and the Units will be subject to a four month hold period.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal's West Island. Aurora also recently aquired Pedanios GmbH, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union ("EU"), based in Berlin, Germany. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the only Australian company licensed to conduct research on and cultivate medical cannabis, Aurora's common shares trade on the TSX-V under the symbol "ACB". Visit www.auroramj.com for more information.
About Radient
Radient extracts natural compounds from a range of biological materials using its proprietary MAP™ natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit www.radientinc.com for more information.
Ready Aurora NR today and keeep in mind we are the exclusive extraction company...RDDTF will not be around by year end.
AURORA ACQUIRES GERMAN MEDICAL CANNABIS MARKET LEADER PEDANIOS GMBH
Aurora Cannabis Inc. has acquired Pedanios GmbH, a leading wholesale importer, exporter and distributor of medical cannabis in the European Union.
Pedanios, a federally licensed medical and narcotic wholesale and GMP-(good manufacturing practices)-inspected narcotic import company, holds all relevant licences and permits, and has been successfully importing, exporting and distributing cannabis for medical purposes since December, 2015, into and within the EU.
In January, 2017, German parliamentarians unanimously passed a new medical cannabis law, which appointed physicians as gatekeepers to access, established pharmacies as the point of sale and introduced full insurance cost coverage for medical cannabis patients across the country. In March, 2017, when the new law came into force, Pedanios's monthly sales immediately doubled, and growth continues to accelerate as Germany's 80 million citizens begin to benefit from the improvements to patient access guaranteed by the new law.
Pedanios wholesales medical cannabis to a growing number of pharmacies -- over 750 as of today -- and offers the widest selection of products of any distributor in the German market, including 10 of the 14 products approved by the Bundesopiumstelle, a body of the German federal health ministry. All of Pedanios's existing supply contracts will remain in place.
"This is a transformational acquisition for Aurora and a key step in our aggressive international expansion strategy," said Neil Belot, Aurora's chief global business development officer. "The transaction will ensure ongoing and increasing high-quality product is available to fuel Pedanios's rapid growth, while positioning Aurora and Pedanios to seize upon opportunities together in Germany and the EU's emerging cannabis industry."
"Pedanios, with first-mover success in the EU, has proven itself as one of the world's most trusted and scalable importers, exporters and distributors of wholesale medical cannabis. Patients, physicians and pharmacies across the EU recognize the Pedanios brand as the trusted source for high-quality GMP-certified medical cannabis," said Terry Booth, chief executive officer of Aurora. "The Pedanios team share Aurora's vision, our high standards and our intentions to play a leading role in shaping the future of the global cannabis industry. In addition, because the average market prices are higher in Germany than in Canada, we expect German sales to positively impact our average sales price per gram."
"Canada and Germany are among the world leaders in medical cannabis, and as trailblazers in our respective countries, Pedanios and Aurora are well positioned to continue to drive innovation, expand our distribution network and capture significant global market share," said Patrick Hoffmann, Pedanios's co-founder and executive partner. "We look forward to the synergies that our combined companies will deliver to shareholders and stakeholders alike."
Under the terms of the purchase agreement, dated May 18, 2017, Aurora will pay a consideration to holders of Class B securities of Pedanios approximately 3,421,756 common shares of Aurora, priced at $2.14 per share. In addition, a total consideration of approximately $13,565,000 in cash and common shares is payable to the holders of Class A common shares of Pedanios, which are held by the two founders/managing directors of Pedanios who will continue to run the company. The cash portion for the two founders is $3.02-million, and the share portion is 4,895,026 common shares of Aurora, priced at $2.14 per share, of which 17 per cent will become free trading four months after closing, with the balance becoming unrestricted in equal instalments on a quarterly basis over 27 months, commencing in February, 2018. Total shares of Aurora being issued over three years represent less than 2 per cent of total shares outstanding. Aurora's cash balance as of May 15, 2017, was $165-million. Values herein have been calculated based on an exchange rate of 1.51 Canadian dollars to one euro.
Pedanios, over the last 90 days, has achieved cash-flow-positive operations, with gross revenues of approximately $1.15-million and costs of approximately $1-million. Revenues for May, up to and including May 26, 2017, were approximately $500,000, reflecting a 410-per-cent increase in the daily sales pace as compared with average for the eight months prior to the introduction of the new law, and an increase over the April and March, 2017, averages of 70 per cent and 108 per cent, respectively.
About Aurora Cannabis Inc.
Aurora's wholly owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's access to cannabis for medical purposes regulations (ACMPR). The company operates a 55,200-square-foot, state-of-the-art production facility in Mountain View county, Alberta, and is currently constructing a second 800,000-square-foot production facility, known as Aurora Sky, at the Edmonton International Airport. Also, it has acquired and is undertaking completion of a third 40,000-square-foot production facility in Pointe-Claire, Que., on Montreal's West Island.